Sandra Calvin insider trades: Travere Therapeutics (TVTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sandra reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TVTX | ↓ Sell | 5,375 | $62.33 | $335K | Direct | Sep 17, 2026 (2d) |
| Apr 14, 2026 | TVTX | ↓ Sell | 21,977 | $41.07 | $903K | Direct | Apr 16, 2026 (2d) |
| Feb 3, 2026 | TVTX | ↓ Sell | 4,333 | $32.12 | $139K | Direct | Feb 3, 2026 (0d) |
| Dec 15, 2025 | TVTX | ↓ Sell | 2,910 | $36.00 | $105K | Direct | Dec 16, 2025 (1d) |
| Nov 4, 2025 | TVTX | ↓ Sell | 67,115 | $36.00 | $2.4M | Direct | Nov 6, 2025 (2d) |
| Feb 11, 2025 | TVTX | ↓ Sell | 34,244 | $25.00 | $856K | Direct | Feb 12, 2025 (1d) |
| Feb 3, 2025 | TVTX | ↓ Sell | 3,348 | $20.12 | $67K | Direct | Feb 4, 2025 (1d) |
| Jan 22, 2025 | TVTX | ↓ Sell | 925 | $18.94 | $18K | Direct | Jan 23, 2025 (1d) |
| Dec 26, 2024 | TVTX | ↓ Sell | 15,000 | $17.22 | $258K | Direct | Dec 27, 2024 (1d) |
| Nov 25, 2024 | TVTX | ↓ Sell | 12,090 | $18.30 | $221K | Direct | Nov 25, 2024 (0d) |
| Feb 1, 2024 | TVTX | ↓ Sell | 2,820 | $8.53 | $24K | Direct | Feb 2, 2024 (1d) |
| Jan 23, 2024 | TVTX | ↓ Sell | 910 | $9.07 | $8K | Direct | Jan 25, 2024 (2d) |
| May 11, 2023 | TVTX | ↓ Sell | 558 | $16.49 | $9K | Direct | May 12, 2023 (1d) |
| Feb 2, 2023 | TVTX | ↓ Sell | 2,031 | $21.87 | $44K | Direct | Feb 2, 2023 (0d) |
| Jan 25, 2023 | TVTX | ↓ Sell | 1,097 | $21.86 | $24K | Direct | Jan 26, 2023 (1d) |
| Sep 13, 2022 | TVTX | ↓ Sell | 349 | $28.00 | $10K | Direct | Sep 15, 2022 (2d) |
| May 11, 2022 | TVTX | ↓ Sell | 881 | $21.72 | $19K | Direct | May 12, 2022 (1d) |
| Jan 31, 2022 | TVTX | ↓ Sell | 798 | $26.51 | $21K | Direct | Feb 2, 2022 (2d) |
| Jan 24, 2022 | TVTX | ↓ Sell | 934 | $24.58 | $23K | Direct | Jan 26, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TVTX insiders
Open-market trades in the last 12 months
About Sandra Calvin's insider trades
Sandra Calvin is SVP, Chief Accounting Officer at Travere Therapeutics (TVTX). Since Jan 24, 2022, Sandra has reported no open-market purchases and 19 sales worth $5.5M on SEC Form 4. In the last 12 months: 4 sales ($1.5M).
Their filings also include option exercises (6 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.